Two Birds with One Stone: Possible Dual-Role of Oxytocin in the Treatment of Diabetes and Osteoporosis

Frontiers in Endocrinology

Volumn 6, Issue , 2015, Pages

  Elabd, Seham ^a   Sabry, Ismail ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b Alexandria University Faculty Of Science   (Egypt)

Author keywords

bone formation; bone resorption; diabetes; glucose uptake; insulin sensitivity; osteoporosis; oxytocin

Indexed keywords

EID: 85011644831     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00121     Document Type: Review

References (62)

1. Lippert TH Mueck AO Seeger H Pfaff A. Effects of oxytocin outside pregnancy. Horm Res (2003) 60(6):262–71.10.1159/00007424314646403
2. Viero C Shibuya I Kitamura N Verkhratsky A Fujihara H Katoh A et al. Oxytocin: crossing the bridge between basic science and pharmacotherapy. CNS Neurosci Ther (2010) 16(5):e138–56.10.1111/j.1755-5949.2010.00185.x20626426
3. Ondrejcakova M Ravingerova T Bakos J Pancza D Jezova D. Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion. Can J Physiol Pharmacol (2009) 87(2):137–42.10.1139/Y08-10819234577
4. Kendall DM Harmel AP. The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care (2002) 8(20):S635–53.12510788
5. Wild S Roglic G Green A Sicree R King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 27(5):1047–53.10.2337/diacare.27.5.104715111519
6. Yamaguchi T. Diabetes mellitus and osteoporosis. How to start drug therapy for osteoporosis in patients with diabetes mellitus. Clin Calcium (2012) 22(9):1403–9. doi:CliCa12091403140922932296
7. Elabd S Sabry I Mohasseb M Algendy A. Oxytocin as a novel therapeutic option for type I diabetes and diabetic osteopathy. Endocr Regul (2014) 48(2):87–102.10.4149/endo_2014_02_8724824804
8. Zhang H Wu C Chen Q Chen X Xu Z Wu J et al. Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models. PLoS One (2013) 8(5):e61477.10.1371/journal.pone.006147723700406
9. Deblon N Veyrat-Durebex C Bourgoin L Caillon A Bussier AL Petrosino S et al. Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats. PLoS One (2011) 6(9):e25565.10.1371/journal.pone.002556521980491
10. Maejima Y Iwasaki Y Yamahara Y Kodaira M Sedbazar U Yada T. Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass. Aging (Albany NY) (2011) 3(12):1169–77.22184277
11. Elabd SK Sabry I Hassan WB Nour H Zaky K. Possible neuroendocrine role for oxytocin in bone remodeling. Endocr Regul (2007) 41(4):131–41.18257653
12. Elabd C Basillais A Beaupied H Breuil V Wagner N Scheideler M et al. Oxytocin controls differentiation of human mesenchymal stem cells and reverses osteoporosis. Stem Cells (2008) 26(9):2399–407.10.1634/stemcells.2008-012718583541
13. Tamma R Colaianni G Zhu LL DiBenedetto A Greco G Montemurro G et al. Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A (2009) 106(17):7149–54.10.1073/pnas.090189010619369205
14. Myers MG Jr Olson DP. Central nervous system control of metabolism. Nature (2012) 491(7424):357–63.10.1038/nature11705
15. Arletti R Benelli A Bertolini A. Oxytocin inhibits food and fluid intake in rats. Physiol Behav (1990) 48(6):825–30.10.1016/0031-9384(90)90234-U2087513
16. Douglas AJ Johnstone LE Leng G. Neuroendocrine mechanisms of change in food intake during pregnancy: a potential role for brain oxytocin. Physiol Behav (2007) 91(4):352–65.10.1016/j.physbeh.2007.04.01217512024
17. Olszewski PK Klockars A Schiöth HB Levine AS. Oxytocin as feeding inhibitor: maintaining homeostasis in consummatory behavior. Pharmacol Biochem Behav (2010) 97(1):47–54.10.1016/j.pbb.2010.05.02620595062
18. Takayanagi Y Kasahara Y Onaka T Takahashi N Kawada T Nishimori K. Oxytocin receptor-deficient mice developed late-onset obesity. Neuroreport (2008) 19(9):951–5.10.1097/WNR.0b013e3283021ca918520999
19. Camerino C. Low sympathetic tone and obese phenotype in oxytocin-deficient mice. Obesity (Silver Spring) (2009) 17(5):980–4.10.1038/oby.2009.1219247273
20. Florian M Jankowski M Gutkowska J. Oxytocin increases glucose uptake in neonatal rat cardiomyocytes. Endocrinology (2010) 151(2):482–91.10.1210/en.2009-062420008042
21. Lee ES Uhm KO Lee YM Kwon J Park SH Soo KH. Oxytocin stimulates glucose uptake in skeletal muscle cells through the calcium-CaMKK-AMPK pathway. Regul Pept (2008) 151(1–3):71–4.10.1016/j.regpep.2008.05.00118555543
22. Knudtzon J. Acute effects of oxytocin and vasopressin on plasma levels of glucagon, insulin and glucose in rabbits. Horm Metab Res (1983) 15:103–4.10.1055/s-2007-1018641
23. Chiodera P Coiro V Camellini L Rossi G Pignatti D Volpi R et al. Effect of pharmacological doses of oxytocin on insulin response to glucose in normal man. Horm Res (1984) 20(2):150–4.10.1159/0001799886386646
24. Paolisso G Sgambato S Giugliano D Pizza G Tesauro P Varricchio M et al. Effects of oxytocin delivery on counter-regulatory hormone response in insulin-dependent (type 1) diabetic subjects. Horm Res (1989) 31:250–5.10.1159/0001811262693310
25. Altszuler N Winkler B Rosenberg CR Pi-Sunyer FX Fuchs AR. Role of insulin and glucagon in oxytocin effects on glucose metabolism. Proc Soc Exp Biol Med (1992) 199(2):236–42.10.3181/00379727-199-433531346936
26. Björkstrand E Eriksson M Uvnäs-Moberg K. Evidence of a peripheral and a central effect of oxytocin on pancreatic hormone release in rats. Neuroendocrinology (1996) 63(4):377–83.10.1159/0001269788739893
27. Zhang G Cai D. Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment. Am J Physiol Endocrinol Metab (2011) 301:E1004–12.10.1152/ajpendo.00196.201121828335
28. Zhang G Bai H Zhang H Dean C Wu Q Li J et al. Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance. Neuron (2011) 69:523–35.10.1016/j.neuron.2010.12.03621315262
29. Altirriba J Poher AL Caillon A Arsenijevic D Veyrat-Durebex C Lyautey J et al. Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes. Endocrinology (2014) 155(11):4189–201.10.1210/en.2014-146625157455
30. Plante E Menaouar A Danalache BA Yip D Broderick TL Chiasson JL et al. Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice. Endocrinology (2015) 156(4):1416–28.10.1210/en.2014-171825562615
31. Zingg HH Laporte SA. The oxytocin receptor. Trends Endocrinol Metab (2003) 14(5):222–7.10.1016/S1043-2760(03)00080-812826328
32. Ku CY Qian A Wen Y Anwer K Sanborn BM. Oxytocin stimulates myometrial guanosine triphosphatase and phospholipase-C activities via coupling to G alpha q/11. Endocrinology (1995) 136(4):1509–15.10.1210/en.136.4.15097895660
33. Phaneuf S Europe-Finner GN Varney M MacKenzie IZ Watson SP López Bernal A. Oxytocin-stimulated phosphoinositide hydrolysis in human myometrial cells: involvement of pertussis toxin-sensitive and -insensitive G-proteins. J Endocrinol (1993) 136(3):497–509.10.1677/joe.0.13604978386215
34. Burns PD Mendes JO Jr Yemm RS Clay CM Nelson SE Hayes SH et al. Cellular mechanisms by which oxytocin mediates ovine endometrial prostaglandin F2alpha synthesis: role of G(i) proteins and mitogen-activated protein kinases. Biol Reprod (2001) 65(4):1150–5.10.1095/biolreprod65.4.115011566737
35. Devost D Carrier M Zingg H. Oxytocin-induced activation of eukaryotic elongation factor 2 in myometrial cells is mediated by protein kinase C. Endocrinology (2008) 149:131–8.10.1210/en.2007-054817947356
36. Sanborn BM. Hormones and calcium: mechanisms controlling uterine smooth muscle contractile activity. The Litchfield Lecture. Exp Physiol (2001) 86(2):223–37.10.1113/eph860217911429639
37. Guzzi F Zanchetta D Cassoni P Guzzi V Francolini M Parenti M et al. Localization of the human oxytocin receptor in caveolin-1 enriched domains turns the receptor-mediated inhibition of cell growth into a proliferative response. Oncogene (2002) 21(11):1658–67.10.1038/sj.onc.120521911896597
38. Koshimizu TA Nakamura K Egashira N Hiroyama M Nonoguchi H Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev (2012) 92(4):1813–64.10.1152/physrev.00035.201123073632
39. Yu H Zhuge R Hsu WH. Lysine vasopressin-induced increases in porcine myometrial contractility and intracellular Ca2+ concentrations of myometrial cells: involvement of oxytocin receptors. Biol Reprod (1995) 52(3):584–90.10.1095/biolreprod52.3.5847756452
40. Schlosser SF Almeida OF Patchev VK Yassouridis A Elands J. Oxytocin-stimulated release of adrenocorticotropin from the rat pituitary is mediated by arginine vasopressin receptors of the V1b type. Endocrinology (1994) 135(5):2058–63.10.1210/endo.135.5.79569277956927
41. Lee B Yang C Chen TH al-Azawi N Hsu WH. Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. Am J Physiol (1995) 269(6 Pt 1):E1095–100.8572202
42. Yibchok-anun S Hsu WH. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors. Life Sci (1998) 63(21):1871–8.10.1016/S0024-3205(98)00463-99825765
43. Cnop M Welsh N Jonas JC Jörns A Lenzen S Eizirik DL. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes (2005) 54(2):S97–107.10.2337/diabetes.54.suppl_2.S9716306347
44. Clark SL Simpson KR Knox GE Garite TJ. Oxytocin: new perspectives on an old drug. Am J Obstet Gynecol (2009) 200(1):.e1–6.10.1016/j.ajog.2008.06.01018667171
45. Jankowski M Bissonauth V Gao L Gangal M Wang D Danalache B et al. Anti-inflammatory effect of oxytocin in rat myocardial infarction. Basic Res Cardiol (2010) 105(2):205–18.10.1007/s00395-009-0076-520012748
46. Szeto A Nation DA Mendez AJ Dominguez-Bendala J Brooks LG Schneiderman N et al. Oxytocin attenuates NADPH-dependent superoxide activity and IL-6 secretion in macrophages and vascular cells. Am J Physiol Endocrinol Metab (2008) 295(6):E1495–501.10.1152/ajpendo.90718.200818940936
47. Eckertova M Ondrejcakova M Krskova K Zorad S Jezova D. Subchronic treatment of rats with oxytocin results in improved adipocyte differentiation and increased gene expression of factors involved in adipogenesis. Br J Pharmacol (2011) 162(2):452–63.10.1111/j.1476-5381.2010.01037.x20846187
48. Oda N Imamura S Fujita T Uchida Y Inagaki K Kakizawa H et al. The ratio of leptin to adiponectin can be used as an index of insulin resistance. Metabolism (2008) 57(2):268–73.10.1016/j.metabol.2007.09.01118191059
49. Yi KJ So KH Hata Y Suzuki Y Kato D Watanabe K et al. The regulation of oxytocin receptor gene expression during adipogenesis. J Neuroendocrinol (2015) 27(5):335–42.10.1111/jne.1226825702774
50. Tontonoz P Hu E Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 79(7):1147–56.10.1016/0092-8674(94)90006-X8001151
51. Bolanowski M Halupczok J Jawiarczyk-Przybyłowska A. Pituitary disorders and osteoporosis. Int J Endocrinol (2015) 2015:206853.10.1155/2015/20685325873948
52. Mc-Cullough ME Churchland PS Mendez AJ. Problems with measuring peripheral oxytocin: can the data on oxytocin and human behavior be trusted? Neurosci Biobehav Rev (2013) 37(8):1485–92.10.1016/j.neubiorev.2013.04.01823665533
53. Rouach V Katzburg S Koch Y Stern N Somjen D. Bone loss in ovariectomized rats: dominant role for estrogen but apparently not for FSH. J Cell Biochem (2011) 112(1):128–37.10.1002/jcb.2290821053364
54. Colucci S Colaianni G Mori G Grano M Zallone A. Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun (2002) 297(3):442–5.10.1016/S0006-291X(02)02009-012270111
55. Copland JA Ives KL Simmons DJ Soloff MS. Functional oxytocin receptors discovered in human osteoblasts. Endocrinology (1999) 140(9):4371–4.10.1210/endo.140.9.713010465312
56. Danciu TE Adam RM Naruse K Freeman MR Hauschka PV. Calcium regulates the PI3K-Akt pathway in stretched osteoblasts. FEBS Lett (2003) 536(1–3):193–7.10.1016/S0014-5793(03)00055-312586362
57. Di Benedetto A Sun L Zambonin CG Tamma R Nico B Calvano CD et al. Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor. Proc Natl Acad Sci U S A (2014) 111(46):16502–7.10.1073/pnas.141934911125378700
58. Tamma R Sun L Cuscito C Lu P Corcelli M Li J et al. Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A (2013) 110(46):18644–9.10.1073/pnas.131825711024167258
59. Thomas T. The complex effects of leptin on bone metabolism through multiple pathways. Curr Opin Pharmacol (2004) 4(3):295–300.10.1016/j.coph.2004.01.00915140423
60. Oshima K Nampei A Matsuda M Iwaki M Fukuhara A Hashimoto J et al. Adiponectin increases bone mass by suppressing osteoclast and activating osteoblast. Biochem Biophys Res Commun (2005) 331(2):520–6.10.1016/j.bbrc.2005.03.21015850790
61. Tachibana M Kagitani-Shimono K Mohri I Yamamoto T Sanefuji W Nakamura A et al. Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorders. J Child Adolesc Psychopharmacol (2013) 23(2):123–7.10.1089/cap.2012.004823480321
62. Anagnostou E Soorya L Brian J Dupuis A Mankad D Smile S et al. Intranasal oxytocin in the treatment of autism spectrum disorders: a review of literature and early safety and efficacy data in youth. Brain Res (2014) 1580:188–98.10.1016/j.brainres.2014.01.04924508578